For years, semaglutide has offered people struggling with obesity a powerful tool — but one that often came wrapped in nausea and muscle loss, a trade-off that left many wondering whether the cure was worth the cost. Now, researchers at the University of Gothenburg have done something quietly profound: they have mapped, with cellular precision, which nerve cells in the brain stem are responsible for the drug's appetite-suppressing benefits, and found them to be distinct from those generating its side effects. Published in Cell Metabolism, the discovery does not yet change what patients experie
News-Medical.net
· May 27, 2025
· health
· 2 min de leitura
High
Apuração: Verificado
Scientists pinpoint brain cells controlling semaglutide's weight loss without nausea
◉
Health & Medicine
8046 artigos relacionados
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 100% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% correspondência
Cobertura Relacionada
Google News · Aug 19
Welsh Teen's Ovarian Cancer Diagnosis Triggers Sudden Menopause
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Viés e Enquadramento
⚖
Article presents scientific research findings on semaglutide's mechanism with optimistic framing about therapeutic potential, minimal apparent bias in reporting factual study results.
Bias Direction
center
Confidence
MED
Progress narrative emphasizing scientific breakthrough and therapeutic promise. Uses hopeful language ('pave the way,' 'could enable') while acknowledging current limitations. Frames research as solution-oriented.
pave the way for better drugs
could enable development of improved obesity treatments
beneficial effects
positive effects
Pharmaceutical industry perspective or potential commercial interests
Patient testimonials or real-world experience with semaglutide side effects
Counterarguments or limitations of mouse model research applicability to humans
Cost/accessibility considerations for potential future treatments
Perspectives from researchers studying alternative obesity treatments
Timeline expectations for translating findings to clinical applications
Impacto Geopolítico
🌎
Swedish researchers identified brain cells controlling semaglutide's weight loss without nausea, enabling development of improved obesity treatments with fewer side effects.
Escalation Risk
low
Confidence
LOW
Pharmaceutical innovation leadership shifts toward Nordic research institutions; potential competitive advantage for Swedish/European biotech companies in obesity drug development market.
Lente Econômica
📈
University of Gothenburg researchers identified brain stem nerve cells controlling semaglutide's weight loss effects without nausea, potentially enabling development of improved obesity drugs with fewer side effects.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Obesity treatment market
Type 2 diabetes treatment market
Consumers could benefit from next-generation obesity and diabetes medications with improved tolerability profiles, potentially reducing treatment discontinuation rates and expanding addressable patient populations who currently avoid GLP-1 agonists due to nausea and muscle loss side effects.
Regulatory agencies (FDA, EMA) may accelerate approval pathways for novel GLP-1 variants with reduced side effect profiles. Healthcare systems may expand coverage as improved safety profiles reduce adverse event management costs. Potential policy focus on obesity treatment accessibility given market expansion opportunities.